The NPM1 mutation, typically a favorable prognostic marker in newly diagnosed AML, loses this advantage in the relapsed/refractory setting. Survival for relapsed NPM1 patients becomes as poor as for those without the mutation, justifying aggressive targeted therapy with menin inhibitors.

Despite clinical efficacy, menin inhibitor monotherapy provides a relatively short duration of response (4-6 months) in the relapsed/refractory setting. Their main clinical benefit is achieving a deep enough remission to allow patients to proceed to a potentially curative allogeneic stem cell transplant.

Initial studies combining menin inhibitors with venetoclax/azacitidine showed high remission rates but also high mortality. Using each agent at its full, 28-day dose caused severe, fatal myelosuppression, forcing protocol amendments to shorten drug exposure to manage toxicity.

Combinations of menin inhibitors with standard chemotherapy are achieving impressively high remission rates (e.g., 89% composite remission) in newly diagnosed KMT2A-rearranged AML. This is a significant development, as this genetic subtype has historically been very challenging to treat effectively.

The differentiation syndrome with menin inhibitors can be far more severe than with other agents, manifesting as a life-threatening, HLH-like state with massive inflammatory marker elevation (e.g., ferritin >300,000) that may be unresponsive to high-dose steroids.

Preclinical data and early clinical findings suggest menin inhibitors could be effective against rare NUP98-rearranged leukemias. This is based on similarities in downstream pathways to the approved KMT2A and NPM1 mutations, hinting at a broader mechanism of action for this drug class.

While adding a menin inhibitor to the azacitidine/venetoclax doublet for older/unfit AML patients increases response rates, it leaves little reserve for marrow function. This can lead to increased risk of early, fatal complications like infection or bleeding, requiring careful dose management.

The future standard of care for AML could move towards all-oral triplet therapies. Citing promising data from the SAVE trial, the speaker suggests these better-tolerated, outpatient regimens could replace harsh inpatient chemotherapy for many patients, improving quality of life.

The new menin inhibitor, enzomenib, demonstrates potentially superior response rates (CR/CRH of 40-60%) compared to existing agents (~23%). Crucially, early data shows no QTc prolongation, a significant dose-limiting toxicity for current menin inhibitors, suggesting a major safety improvement for this drug class.